Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine placental extracellular matrix (PPECM), commercially known as InnovaMatrix AC, is a decellularized and terminally sterilized topical wound covering derived from porcine placental amnion and chorion tissue. Developed by Convatec (formerly Triad Life Sciences), it is classified as a cellular, acellular, and matrix-like product (CAMP). The matrix retains essential biological components, including collagen, elastin, laminin, fibronectin, hyaluronic acid, and sulfated glycosaminoglycans, which collectively provide a structural scaffold to support the wound healing microenvironment. It is FDA-cleared for the management of a wide range of acute and chronic wounds, such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and partial-thickness burns, and has been shown to reduce complications like amputation and bacteremia compared to standard care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on porcine placental extracellular matrix.